New lung drug put to the test: will it harm the heart?
NCT ID NCT06107036
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 trial tested whether a single dose of the experimental drug BI 1015550 (nerandomilast) affects the heart's electrical activity in 46 healthy adults. Participants received low and high doses of the drug, a placebo, and an open-label heart-safe drug (moxifloxacin) for comparison. The goal was to see if BI 1015550 causes any dangerous changes in heart rhythm, which is important for future studies in patients with lung conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 1015550 (nerandomilast)
What this could lead to
If the drug shows no heart risks, it could support safer use in future trials for conditions like lung fibrosis.
What could go wrong
This is an early safety study in healthy people, not patients. It cannot predict if the drug works for any disease or if rare heart effects appear later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Quotient Sciences
Nottingham, NG11 6JS, United Kingdom